Revenue Breakdown
Composition ()
No data
Revenue Streams
InterCure Ltd (INCR) generates its revenue primarily from Cannabis Segment, which accounts for 100.0% of total sales, equivalent to ILS 106.17M. Understanding this concentration is critical for investors evaluating how INCR navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, InterCure Ltd maintains a gross margin of 30.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.59%, while the net margin is -17.87%. These profitability ratios, combined with a Return on Equity (ROE) of -12.96%, provide a clear picture of how effectively INCR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, INCR competes directly with industry leaders such as INGN and EDAP. With a market capitalization of $48.29M, it holds a significant position in the sector. When comparing efficiency, INCR's gross margin of 30.47% stands against INGN's 44.72% and EDAP's 43.02%. Such benchmarking helps identify whether InterCure Ltd is trading at a premium or discount relative to its financial performance.
